BC Extra | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

Lloyd Sanders will succeed Murali Prahalad as president and CEO of cancer diagnostic company Epic Sciences Inc. (San Diego, Calif.). Sanders was president of the oncology segment of molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN)....
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II...
BC Innovations | May 31, 2018
Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
BioCentury | Oct 13, 2017
Regulation

Expanding the HAE tool kit

Despite an increasingly crowded market, hereditary angioedema patients who attended FDA’s Patient-Focused Drug Development meeting said there remains room for improvement in dosing convenience and reducing attack frequency. Two subcutaneous prophylactics that have completed Phase...
BC Week In Review | Oct 13, 2017
Company News

KalVista leaps after Merck deal in DME

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares jumped 38% on Oct. 10 after the company granted Merck & Co. Inc. (NYSE:MRK) options to acquire its most advanced program KVD001 , an intravitreal plasma kallikrein (KLKB1) inhibitor, along with...
BC Extra | Oct 10, 2017
Company News

KalVista leaps after Merck deal in DME

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares jumped $2.79 (38%) to $10.17 on Tuesday after the company granted Merck & Co. Inc. (NYSE:MRK) options to acquire its most advanced program KVD001 , an intravitreal plasma kallikrein inhibitor (KLKB1),...
BC Week In Review | Jun 27, 2016
Company News

KalVista, Carbylan Therapeutics deal

Carbylan will merge with KalVista in a stock deal, with KalVista expected to own an 81% stake in the combined company. The combined company will focus on KalVista’s pipeline, which includes KVD001 , an intravitreal plasma...
BC Week In Review | Jul 27, 2015
Financial News

KalVista completes venture financing

KalVista Pharmaceuticals Ltd. , Salisbury, U.K.   Business: Ophthalmic   Date completed: 2015-07-22   Type: Venture financing   Raised: $33 million   Investors: Novo A/S ; SV Life Sciences ; RA Capital Management; Longwood Fund; Venrock...
BC Extra | Jul 24, 2015
Financial News

KalVista raises $33M in series B

KalVista Pharmaceuticals Ltd. (Salisbury, U.K.) raised $33 million in a series B round led by new investor RA Capital. New investors Longwood Fund and Venrock and existing investors Novo A/S and SV Life Sciences also...
BC Week In Review | Sep 15, 2014
Clinical News

KVD001: Phase I started

KalVista began an open-label, U.S. Phase I trial to evaluate single ascending doses of intravitreal KVD001 in about 17 patients. KalVista Pharmaceuticals Ltd. , Southampton, U.K.   Product: KVD001   Business: Ophthalmic   Molecular target: NA...
Items per page:
1 - 10 of 20
BC Extra | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

Lloyd Sanders will succeed Murali Prahalad as president and CEO of cancer diagnostic company Epic Sciences Inc. (San Diego, Calif.). Sanders was president of the oncology segment of molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN)....
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II...
BC Innovations | May 31, 2018
Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
BioCentury | Oct 13, 2017
Regulation

Expanding the HAE tool kit

Despite an increasingly crowded market, hereditary angioedema patients who attended FDA’s Patient-Focused Drug Development meeting said there remains room for improvement in dosing convenience and reducing attack frequency. Two subcutaneous prophylactics that have completed Phase...
BC Week In Review | Oct 13, 2017
Company News

KalVista leaps after Merck deal in DME

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares jumped 38% on Oct. 10 after the company granted Merck & Co. Inc. (NYSE:MRK) options to acquire its most advanced program KVD001 , an intravitreal plasma kallikrein (KLKB1) inhibitor, along with...
BC Extra | Oct 10, 2017
Company News

KalVista leaps after Merck deal in DME

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares jumped $2.79 (38%) to $10.17 on Tuesday after the company granted Merck & Co. Inc. (NYSE:MRK) options to acquire its most advanced program KVD001 , an intravitreal plasma kallikrein inhibitor (KLKB1),...
BC Week In Review | Jun 27, 2016
Company News

KalVista, Carbylan Therapeutics deal

Carbylan will merge with KalVista in a stock deal, with KalVista expected to own an 81% stake in the combined company. The combined company will focus on KalVista’s pipeline, which includes KVD001 , an intravitreal plasma...
BC Week In Review | Jul 27, 2015
Financial News

KalVista completes venture financing

KalVista Pharmaceuticals Ltd. , Salisbury, U.K.   Business: Ophthalmic   Date completed: 2015-07-22   Type: Venture financing   Raised: $33 million   Investors: Novo A/S ; SV Life Sciences ; RA Capital Management; Longwood Fund; Venrock...
BC Extra | Jul 24, 2015
Financial News

KalVista raises $33M in series B

KalVista Pharmaceuticals Ltd. (Salisbury, U.K.) raised $33 million in a series B round led by new investor RA Capital. New investors Longwood Fund and Venrock and existing investors Novo A/S and SV Life Sciences also...
BC Week In Review | Sep 15, 2014
Clinical News

KVD001: Phase I started

KalVista began an open-label, U.S. Phase I trial to evaluate single ascending doses of intravitreal KVD001 in about 17 patients. KalVista Pharmaceuticals Ltd. , Southampton, U.K.   Product: KVD001   Business: Ophthalmic   Molecular target: NA...
Items per page:
1 - 10 of 20